a Adjusted for age, sex, BMI, race, asthma, COVPD, HF,
DM,ESRD Aldosterone antagonist and steroid use.
The Kaplan-Meier curve illustrated that ACEI/ARBs were associated with
increased COVID-19 mortality (Figure 3). Similarly, the unadjusted Cox
proportional hazard model showed that the use of ACEI/ARBs was
associated with an increase in COVID-19 mortality (HR= 1.25, 95%
CI[1.01, 1.54), p-value= 0.03). However, we failed to find a
statistically significant association between the history of ACEI/ARB
use and 30 days-COVID-19 survival in the adjusted Cox proportional
hazard model (Table 4).
Figure 3: Kaplan-Meier curve demonstrating the association between the
use of ACEI/ARBS and COVID-19 mortality.